Finoriq research workspace
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Historical Metrics
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the. Review ARWR valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
- Company
- ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- Ticker
- ARWR
- Market Cap
- $10.1B
- Latest Price
- $71.69
- Industry
- Biotech & Pharma
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Current Valuation Metrics
Static valuation preview for ARROWHEAD PHARMACEUTICALS, INC. (ARWR). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 19.4x | Revenue | TTM Q2 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -2.5% | Net Income | TTM Q2 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -0.3% | Operating Cash Flow | TTM Q2 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 19.7x | Stockholders' Equity | Q2 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.